| Nov-12-10 |
Cortex Reports Third Quarter 2010 Operating Results |
| Nov-10-10 |
First Joint Cortex-Servier High-Impact Ampakine Compound Moves into Phase I Clinical Studies |
| Oct-6-10 |
Cortex Obtains Exclusive Worldwide Rights for the Combination of AMPAKINE® and mGluR5 Compounds for the Treatment of Fragile X |
| Oct-1-10 |
Cortex Regains Rights to Develop its AMPAKINE Compounds to treat Depression and Schizophrenia |
| Sep-10-10 |
Cortex’s CEO to Present at Rodman & Renshaw’s 12th Annual Healthcare Conference on September 13, 2010 |
| Aug-16-10 |
Cortex Reports Second Quarter Operating Results |
| July-6-10 |
Cortex Receives Funding from The Michael J. Fox Foundation to discover drug candidates for Parkinson’s disease |
| May-17-10 |
Cortex Reports First Quarter Operating Results |
| May-14-10 |
Cortex To Hold Annual Shareholder Meeting on May 19 at Marriott Newport Beach Hotel in Newport Beach, CA |
| Apr-8-10 |
Cortex Reports Fourth Quarter and Year End Operating Results |
| Mar-26-10 |
Cortex Sells Selected Ampakine Compounds and Rights to Respiratory Depression Indication to Biovail |
| Jan-15-10 |
Cortex Announces $1.5 Million Private Placement |